Healio Minute

In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more. Read the full coverage here…

In this edition, FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy, ivonescimab ‘may be a new standard’ and more. Read the full coverage here:

FDA approves first subcutaneous anti-PD-…

In this edition, enrollment and dosing complete in phase 1 trial of AIV007, popular benchmarks in clinical practice guidelines and more. Read the full coverage here:

Enrollment, dosing complete in …

In this edition, drug discounts through Medicare price negotiations, opioid use has fallen 15% annually since 2014 and more. Read the full coverage here:

Enbrel, Stelara to be discounted nearly 70%…

In this edition, low education level raises follow-up risk in screening program, screening judgement strongly influenced by clinicians and more. Read the full coverage here:

Low education level rai…

In this edition, sozinibercept combination therapy shows durability, comparable improvements with aflibercept and more. Read the full coverage here:

Sozinibercept combination therapy shows durabili…

In this edition, guselkumab brings ‘stringent’ control through 2 years, SARDs outpatient visits result in opioid prescriptions and more. Read the full coverage here:

Guselkumab brings active psoria…

In this edition, atezolizumab benefits PD-L1-selected patients with NSCLC, risks persist with e-cigarette use after quitting tobacco smoking and more. Read the full coverage here:

Adjuvant atezoliz…

In this edition, FDA approves Vabysmo prefilled syringe for retinal diseases, 4D Molecular Therapeutics updates on retinal disease candidates and more. Read the full coverage here:

FDA approves Vab…

In this edition, extensive psoriasis and IBD history predict difficult-to-treat psoriatic arthritis, targeted therapies demonstrate low risk for serious infection and more. Read the full coverage he…

In this edition, screening program identifies airways disease in previously undiagnosed COPD, positive results show benefits of subcutaneous bispecifics and more. Read the full coverage here:

Lung …

In this edition, AI model helps predict anti-VEGF response in DME, Merck to acquire EyeBio and more. Read the full coverage here:

VIDEO: AI model helps predict anti-VEGF response in diabetic macula…

In this edition, difficult-to-treat psoriatic arthritis 'not all about the therapies', Samsung biosimilar comparable to etanercept and more. Read the full coverage here:

Difficult-to-treat psoriati…

In this edition, smoking cessation support uptake at lung cancer screenings, glecirasib may deliver ‘efficacy and tolerability advantages’ and more. Read the full coverage here:

Uptake of smoking c…

In this edition, FDA accepts new drug application for Eluminex, most mentors in vitreoretinal subspecialty are men and more. Read the full coverage here:

FDA accepts investigational new drug applic…

In this edition, FDA approves Selarsdi as Stelara biosimilar, deucravacitinib improves ‘broad range’ of patient-reported outcomes and more. Read the full coverage here:

FDA approves Selarsdi as Ste…

In this edition, durvalumab improves survival in limited-stage small cell lung cancer, most adults do not test homes for radon exposure and more. Read the full coverage here:

Durvalumab improves su…

In this edition, PALADIN study navigates IOP-lowering surgery in DME patients, small-molecule eye drop well-tolerated as treatment for retinal vascular diseases and more. Read the full coverage here…

In this edition, race identified as risk factor for VTE, FDA approves Rybrevant for treatment of non-small cell lung cancer and more. Read the full coverage here:

Race identified as risk factor for…

In this edition, blood test for lung cancer patients who may benefit from further immunotherapy, invasive procedures following lung cancer screenings and more. Read the full coverage here:

Blood te…